Table 2.
Product Type | Contracting Arrangement* | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||||
HMO N |
PPO N |
POS N |
CDP** N |
External N |
Internal N |
||||||||
Number of Products | |||||||||||||
2003 | 2,209 | 2,619 | 2,702 | – | 5,471 | 1,147 | |||||||
2010 | 2,420 | 3,004 | 2,613 | 390 | 1,219 | 7,177 | |||||||
2014 | 2,355 | 2,478 | 900 | 1,241 | 701 | 6,273 | |||||||
| |||||||||||||
% | SE | % | SE | % | SE | % | SE | % | SE | % | SE | ||
| |||||||||||||
Opioid Treatment Programs | |||||||||||||
Coverage | |||||||||||||
2003 | 66.6 | 3.9 | 57.9a | 3.5 | 68.3a | 2.4 | – | – | 67.7f | 2.6 | 35.9f | 7.6 | |
2010 | 80.2a | 2.8 | 70.7a | 2.3 | 67.4a | 2.0 | 0.4a | 0.3 | 34.9f | 6.7 | 74.6f | 1.2 | |
2014 | 96.4 | 1.2 | 97.9 | 0.6 | 96.4 | 2.2 | 96.7 | 2.4 | 98.0 | 0.9 | 96.8 | 1.3 | |
Prior Authorization | |||||||||||||
2003 | 93.5a | 3.5 | 42.0a,b | 8.8 | 94.3b | 3.5 | – | – | 94.0 | 1.6 | 57.3 | 18.7 | |
2010 | 72.2a | 2.0 | 69.7bc | 2.3 | 77.1bd | 1.7 | 99.6acd | 0.3 | 93.2f | 2.4 | 71.2f | 1.7 | |
2014 | 35.9ab | 2.7 | 36.4cd | 2.4 | 15.2ace | 3.8 | 53.1bde | 3.2 | 78.7f | 8.4 | 31.8f | 2.1 | |
Continuing Review | |||||||||||||
2003 | 91.5ab | 2.2 | 54.3bc | 5.6 | 98.9ac | 0.4 | – | – | 95.0 | 1.4 | 82.2 | 7.4 | |
2010 | 70.2ab | 2.6 | 70.2cd | 1.9 | 73.9ace | 1.6 | 100.0bde | – | 100.0f | – | 68.7f | 1.4 | |
2014 | 44.9a | 1.4 | 45.9b | 2.4 | 23.4abc | 5.0 | 50.8c | 3.2 | 96.4f | 1.4 | 38.2f | 1.9 | |
| |||||||||||||
Buprenorphine Pharmacy*** | |||||||||||||
Coverage | |||||||||||||
2003 | 63.0a,b | 2.5 | 94.3b,c | 1.6 | 55.2a,c | 3.0 | – | – | 64.3f | 1.9 | 84.5f | 5.2 | |
2010 | 100.0 | – | 100.0 | – | 100.0 | – | 100.0 | – | 100.0 | – | 100.0 | – | |
Prior Authorization | |||||||||||||
2003 | 8.3 | 2.4 | 9.8 | 1.7 | 4.7 | 1.9 | – | – | 7.3 | 1.7 | 12.5 | 8.5 | |
2010 | 31.3abc | 2.1 | 36.6ad | 3.0 | 39.6bd | 2.4 | 99.6cd | 0.3 | 63.0f | 5.4 | 34.9f | 2.7 |
Excludes “comprehensive” products
CDP was not asked in 2003
Buprenorphine pharmacy was not asked in 2014
Significance testing compared categories within a year (row). Pairs with the same superscript within a row and section indicate significant differences at p<.05.